Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(a month from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(7 years from now) | |
US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) |
Pepaxto is owned by Oncopeptides Ab.
Pepaxto contains Melphalan Flufenamide Hydrochloride.
Pepaxto has a total of 6 drug patents out of which 0 drug patents have expired.
Pepaxto was authorised for market use on 26 February, 2021.
Pepaxto is available in powder;intravenous dosage forms.
Pepaxto can be used as in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy.
Drug patent challenges can be filed against Pepaxto from 26 February, 2025.
The generics of Pepaxto are possible to be released after 25 April, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER;INTRAVENOUS